Novo Nordisk Return on Tangible Equity 2010-2022 | NVO

Current and historical return on tangible equity values for Novo Nordisk (NVO) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Novo Nordisk Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2022-06-30 $7.63B $4.27B 157.52%
2022-03-31 $7.70B $3.50B 137.06%
2021-12-31 $7.60B $4.39B 120.89%
2021-09-30 $7.45B $7.23B 109.12%
2021-06-30 $7.14B $7.34B 102.24%
2021-03-31 $6.74B $6.18B 94.29%
2020-12-31 $6.46B $6.54B 87.23%
2020-09-30 $6.23B $7.88B 80.83%
2020-06-30 $6.13B $8.02B 81.50%
2020-03-31 $6.01B $7.17B 82.34%
2019-12-31 $5.84B $7.76B 82.24%
2019-09-30 $5.62B $7.14B 80.92%
2019-06-30 $5.51B $7.11B 80.65%
2019-03-31 $5.72B $6.40B 83.49%
2018-12-31 $5.91B $7.14B 85.43%
2018-09-30 $6.16B $6.69B 89.36%
2018-06-30 $6.30B $7.19B 90.28%
2018-03-31 $6.11B $6.64B 88.96%
2017-12-31 $5.79B $7.06B 88.36%
2017-09-30 $5.73B $7.00B 89.87%
2017-06-30 $5.65B $6.77B 93.21%
2017-03-31 $5.69B $5.38B 96.39%
2016-12-31 $5.64B $6.32B 96.16%
2016-09-30 $5.59B $5.77B 93.95%
2016-06-30 $5.37B $6.15B 88.62%
2016-03-31 $5.09B $5.20B 86.05%
2015-12-31 $5.19B $6.67B 89.75%
2015-09-30 $5.08B $6.21B 86.81%
2015-06-30 $4.98B $5.58B 84.14%
2015-03-31 $5.03B $4.66B 82.05%
2014-12-31 $4.72B $6.94B 73.39%
2014-09-30 $4.74B $6.51B 72.60%
2014-06-30 $4.72B $6.42B 71.94%
2014-03-31 $4.61B $5.86B 71.75%
2013-12-31 $4.49B $7.29B 70.19%
2013-09-30 $4.38B $6.65B 70.04%
2013-06-30 $4.20B $5.91B 69.58%
2013-03-31 $3.94B $5.71B 67.42%
2012-12-31 $3.70B $6.76B 64.08%
2012-09-30 $3.53B $5.75B 61.18%
2012-06-30 $3.36B $5.16B 56.56%
2012-03-31 $3.24B $5.45B 50.84%
2011-12-31 $3.16B $6.72B 48.41%
2011-09-30 $3.06B $6.45B 47.56%
2011-06-30 $2.94B $6.85B 47.09%
2011-03-31 $2.77B $6.10B 46.79%
2010-12-31 $2.62B $6.33B 44.60%
2010-09-30 $2.35B $5.71B 39.74%
2010-06-30 $2.23B $5.55B 36.46%
2010-03-31 $2.15B $5.91B 34.42%
2009-12-31 $2.03B $6.50B 33.35%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $215.616B $22.397B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $435.655B 16.59
Eli Lilly (LLY) United States $292.179B 37.05
AbbVie (ABBV) United States $249.673B 10.61
Pfizer (PFE) United States $245.989B 7.21
Merck (MRK) United States $218.318B 11.40
Novartis AG (NVS) Switzerland $165.082B 12.17